{"denoms":[{"counts":[{"groupId":"BG000","value":"396"},{"groupId":"BG001","value":"396"},{"groupId":"BG002","value":"792"}],"units":"Participants"}],"groups":[{"description":"Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or intravenously on days 1, 8, 15, and 22.","id":"BG000","title":"Lenalidomide and Dexamethasone (Rd)"},{"description":"Participants received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, then escalated to 27 mg/m² on Days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 of every cycle. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 of every cycle.","id":"BG001","title":"Carfilzomib, Lenalidomide, and Dexamethasone (CRd)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.04","value":"64.5"},{"groupId":"BG001","spread":"9.21","value":"63.3"},{"groupId":"BG002","spread":"9.14","value":"63.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"181"},{"groupId":"BG002","value":"345"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"232"},{"groupId":"BG001","value":"215"},{"groupId":"BG002","value":"447"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"Asian/Native Hawaiian or Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"23"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"377"},{"groupId":"BG001","value":"377"},{"groupId":"BG002","value":"754"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"154"}],"title":"< 2.5 mg/L"},{"measurements":[{"groupId":"BG000","value":"319"},{"groupId":"BG001","value":"319"},{"groupId":"BG002","value":"638"}],"title":"≥ 2.5 mg/L"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Serum β2 Microglobulin","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"261"},{"groupId":"BG001","value":"261"},{"groupId":"BG002","value":"522"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"135"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"270"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Bortezomib Exposure","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"158"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"318"},{"groupId":"BG001","value":"316"},{"groupId":"BG002","value":"634"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Prior Lenalidomide Exposure","unitOfMeasure":"Participants"}]}